Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study.

ABSTRACT:

Background

Treatment of advanced or metastatic esophageal adenocarcinoma (EAC) follows the guidelines for gastroesophageal junction adenocarcinoma (GEJC) and gastric adenocarcinoma (GAC), but patients with EAC are often excluded from clinical studies of GEJC/GAC.

Objectives

Here we describe treatment and survival of patients with advanced EAC, GEJC, and GAC to provide population-based evidence on distinctions and similarities between these populations.

Design

Retrospective cohort study of patients with unresectable advanced (cT4b) or metastatic (cM1) EAC, GEJC, or GAC (2015-2020) were selected from the Netherlands Cancer Registry.

Methods

Overall survival (OS) was assessed using Kaplan-Meier methods, log-rank tests, and multivariable Cox regression.

Results<

SUBMITTER: Pape M 

PROVIDER: S-EPMC10031599 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature